Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Melanoma 28Carcinoma, Renal Cell 19Carcinoma, Non-Small-Cell Lung 13Carcinoma, Hepatocellular 10Brain Neoplasms 7Skin Neoplasms 6Neoplasm Metastasis 6Clear-cell metastatic renal cell carcinoma 6Neoplasms 5Kidney Neoplasms 5Colorectal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Lung Neoplasms 4Carcinoma, Transitional Cell 4Triple Negative Breast Neoplasms 3Multiple Myeloma 3Mesothelioma 3Liver Neoplasms 3Breast Neoplasms 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Sarcoma 2Recurrence 2Prostatic Neoplasms 2Mesothelioma, Malignant 2Lymphoma, Non-Hodgkin 2Glioblastoma 2Colonic Neoplasms 2

Interventions

toripalimab 2pembrolizumab 2Celecoxib 2sintilimab 1dostarlimab 1camrelizumab 1Radiation Dose Hypofractionation 1Nivolumab 1Neoadjuvant Therapy 1Ipilimumab 1Interleukin-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Turcot syndrome × Ipilimumab × Clear all
NCT06362369 2026-04-13

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

7 Hills Pharma, LLC

Phase 1/2 Recruiting
126 enrolled
DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Turcot syndrome, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡